|
1.
The effect of human chorionic gonadotropin (hCG) in the treatment ... hCG (or CG) in combination with restricted diet, daily group sessions, lectures on diet, obesity and behaviour or weekly supporting interviews. ... 2.
Cost-effectiveness analysis of sequential paclitaxel adjuvant ... The sensitivity analysis showed that the cost per QALY was extremely sensitive to variations in paclitaxel cost and effectiveness. ... 3.
Cost-utility model comparing docetaxel and paclitaxel in advanced ... The incremental cost per QALY was $8615 for docetaxel versus paclitaxel, calculated as cost of docetaxel - cost of paclitaxel/ utility of docetaxel- utility ... 4.
Drug-eluting stents versus bare metal stents in percutaneous ... Jan 31, 2006 ... This review concluded that drug-eluting stents used in coronary disease ... The results for nonpolymer paclitaxel-eluting stents showed no ... 5.
Cost-effectiveness of midwifery services vs. medical services in ... Comparison of midwifery care to medical care in hospitals in the Quebec Pilot Projects Study: clinical indicators. Canadian Journal of Public Health 2000 ... 6.
Systematic review of endoscopic sinus surgery for nasal polyps Mar 31, 2005 ... Systematic review of endoscopic sinus surgery for nasal polyps ... endoscopic sinus surgery (FESS) for the removal of nasal polyps. ... 7.
Octaplas compared with fresh frozen plasma to reduce the risk of ... "This study investigates the cost-effectiveness position of Octaplas against standard FFP, and its budgetary impact to the health care system. ... 8.
Health economics assessment study of teicoplanin versus vancomycin ... Jan 31, 2007 ... Teicoplanin offered a better safety profile in comparison with vancomycin for the treatment of Gram-positive infections, but there were no ... 9.
Cost-effectiveness analysis of linezolid compared with vancomycin ... Feb 28, 2007 ... The objective of the study was to compare the cost-effectiveness of linezolid and vancomycin in the treatment of patients with NP caused by ... 10.
Chemotherapy in gastric cancer: an economic evaluation of the FAM ... All patients treated before April 1992 received FAM chemotherapy (17). After this date, patients (9) were treated with ELF chemotherapy because of promising ... |
